SG11201912429RA - Personalized vaccine - Google Patents
Personalized vaccineInfo
- Publication number
- SG11201912429RA SG11201912429RA SG11201912429RA SG11201912429RA SG11201912429RA SG 11201912429R A SG11201912429R A SG 11201912429RA SG 11201912429R A SG11201912429R A SG 11201912429RA SG 11201912429R A SG11201912429R A SG 11201912429RA SG 11201912429R A SG11201912429R A SG 11201912429RA
- Authority
- SG
- Singapore
- Prior art keywords
- personalized vaccine
- personalized
- vaccine
- Prior art date
Links
- 229940038309 personalized vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305760 | 2017-06-21 | ||
| EP18305496 | 2018-04-23 | ||
| PCT/EP2018/066668 WO2018234506A2 (en) | 2017-06-21 | 2018-06-21 | Personalized vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912429RA true SG11201912429RA (en) | 2020-01-30 |
Family
ID=62599637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912429RA SG11201912429RA (en) | 2017-06-21 | 2018-06-21 | Personalized vaccine |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230277639A1 (en) |
| EP (1) | EP3641803A2 (en) |
| JP (2) | JP7334124B2 (en) |
| KR (1) | KR20200026894A (en) |
| CN (1) | CN111065406A (en) |
| AU (1) | AU2018287159A1 (en) |
| CA (1) | CA3067405A1 (en) |
| IL (1) | IL271558B2 (en) |
| SG (1) | SG11201912429RA (en) |
| WO (1) | WO2018234506A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020176797A1 (en) * | 2019-02-27 | 2020-09-03 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| EP3842065A1 (en) | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| CN111303277A (en) * | 2020-02-19 | 2020-06-19 | 中国人民解放军军事科学院军事医学研究院 | An immunoglobulin F (ab') for resisting smallpox virus2And method for preparing the same |
| WO2024062098A1 (en) | 2022-09-23 | 2024-03-28 | Transgene | Recombinant pseudocowpox virus encoding an interleukin-12 |
| CN116656730B (en) * | 2023-05-25 | 2024-03-19 | 军事科学院军事医学研究院军事兽医研究所 | Recombinant canary pox virus expressing rabies virus G, M protein and construction method thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (en) | 1997-07-18 | 1999-01-22 | Transgene Sa | ANTITUMOR COMPOSITION BASED ON MODIFIED IMMUNOGENIC POLYPEPTIDE WITH CELL LOCATION |
| FR2790955B1 (en) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
| UA82466C2 (en) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Method for intensification of chordopoxvirus amplification |
| HUP0402179A3 (en) | 2001-12-10 | 2012-09-28 | Bavarian Nordic As | Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions |
| PT1646715E (en) | 2003-07-22 | 2010-08-09 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| JP5138601B2 (en) | 2005-11-21 | 2013-02-06 | サノフィ パストゥール リミテッド | Recombinant virus stabilization formulation |
| RS51525B (en) | 2006-01-05 | 2011-06-30 | Transgene Sa. | Avian telomerase reverse transcriptase |
| AU2007263280B2 (en) * | 2006-06-20 | 2012-09-13 | Transgene S.A. | Process for producing poxviruses and poxvirus compositions |
| TW200840869A (en) | 2007-01-30 | 2008-10-16 | Transgene Sa | Papillomavirus vaccine |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| JP2010526546A (en) | 2007-05-14 | 2010-08-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | Purification of vaccinia virus and recombinant vaccinia virus vaccines |
| CN101743250A (en) | 2007-05-15 | 2010-06-16 | 特兰斯吉恩股份有限公司 | Signaling peptides |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| AU2008270317B2 (en) | 2007-07-03 | 2013-12-05 | Transgene S.A. | Immortalized avian cell lines |
| EP2212423B1 (en) | 2007-11-19 | 2015-02-11 | Transgene SA | Poxviral oncolytic vectors |
| BRPI0820576B1 (en) | 2007-11-19 | 2021-10-19 | Transgène S.A. | USE OF AN ONCOLYTIC POXVIRUS COMPRISING A DEFECTIVE I4L AND/OR F4L GENE OR A COMPOSITION COMPRISING THE SAME |
| WO2009100521A1 (en) | 2008-02-12 | 2009-08-20 | Sanofi Pasteur Limited | Methods using ion exchange and gel filtration chromatography for poxvirus purification |
| EP2199400A1 (en) * | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| US8609392B2 (en) | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
| SG193553A1 (en) | 2011-05-24 | 2013-10-30 | Biontech Ag | Individualized vaccines for cancer |
| PL2739293T3 (en) | 2011-08-05 | 2020-11-16 | Sillajen Biotherapeutics, Inc. | Methods and compositions for production of vaccina virus |
| TWI690322B (en) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | Virus-containing formulation and use thereof |
| AU2014251207B2 (en) * | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| NZ721105A (en) * | 2013-12-06 | 2022-04-29 | Broad Inst Inc | Formulations for neoplasia vaccines |
| WO2015175340A1 (en) | 2014-05-13 | 2015-11-19 | Bavarian Nordic, Inc. | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
| NZ725459A (en) | 2014-05-13 | 2023-04-28 | Bavarian Nordic As | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| IL255769B2 (en) | 2015-05-20 | 2023-09-01 | Broad Inst Inc | Shared neoantigens |
| AU2016267155A1 (en) | 2015-05-26 | 2017-12-21 | Advaxis, Inc. | Personalized delivery vector-based immunotherapy and uses thereof |
| TW201717974A (en) | 2015-06-24 | 2017-06-01 | 艾法西斯公司 | Manufacturing device and process for personalized delivery vector-based immunotherapy |
-
2018
- 2018-06-21 JP JP2019570982A patent/JP7334124B2/en active Active
- 2018-06-21 EP EP18731146.9A patent/EP3641803A2/en active Pending
- 2018-06-21 CA CA3067405A patent/CA3067405A1/en active Pending
- 2018-06-21 AU AU2018287159A patent/AU2018287159A1/en active Pending
- 2018-06-21 SG SG11201912429RA patent/SG11201912429RA/en unknown
- 2018-06-21 WO PCT/EP2018/066668 patent/WO2018234506A2/en unknown
- 2018-06-21 KR KR1020207001211A patent/KR20200026894A/en not_active Application Discontinuation
- 2018-06-21 CN CN201880050941.2A patent/CN111065406A/en active Pending
- 2018-06-21 IL IL271558A patent/IL271558B2/en unknown
-
2023
- 2023-04-13 US US18/299,858 patent/US20230277639A1/en active Pending
- 2023-06-19 JP JP2023100296A patent/JP2023123609A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL271558B2 (en) | 2024-01-01 |
| WO2018234506A3 (en) | 2019-03-07 |
| JP2023123609A (en) | 2023-09-05 |
| EP3641803A2 (en) | 2020-04-29 |
| IL271558B1 (en) | 2023-09-01 |
| KR20200026894A (en) | 2020-03-11 |
| RU2020101489A (en) | 2021-07-21 |
| US20200138923A1 (en) | 2020-05-07 |
| CN111065406A (en) | 2020-04-24 |
| JP2020530437A (en) | 2020-10-22 |
| AU2018287159A1 (en) | 2020-01-16 |
| RU2020101489A3 (en) | 2021-10-21 |
| US20230277639A1 (en) | 2023-09-07 |
| WO2018234506A2 (en) | 2018-12-27 |
| IL271558A (en) | 2020-02-27 |
| CA3067405A1 (en) | 2018-12-27 |
| JP7334124B2 (en) | 2023-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201806688D0 (en) | No details | |
| GB201803663D0 (en) | No details | |
| GB201801258D0 (en) | No details | |
| GB201813366D0 (en) | No details | |
| GB201518684D0 (en) | Vaccine | |
| GB201721011D0 (en) | No details | |
| IL271558B1 (en) | Personalized vaccine | |
| GB201801628D0 (en) | No details | |
| GB201807647D0 (en) | No details | |
| GB201522132D0 (en) | Vaccine | |
| GB201710451D0 (en) | Comford aid | |
| GB201717719D0 (en) | No details | |
| GB201616904D0 (en) | Vaccine | |
| GB201811353D0 (en) | No details | |
| GB201802344D0 (en) | No details | |
| GB201720890D0 (en) | No details | |
| GB201709043D0 (en) | No details | |
| GB201608821D0 (en) | Vaccines | |
| IL267264A (en) | Adjuvants | |
| EP3568471A4 (en) | Personalized vaccines | |
| GB201811382D0 (en) | Vaccine | |
| GB201811817D0 (en) | No details | |
| GB201801239D0 (en) | No details | |
| GB201621375D0 (en) | Adjuvants | |
| GB201618479D0 (en) | Adjuvants |